



Program Announcement for the Defense Health Agency

Kidney Cancer Research Program Idea Development Award

Funding Opportunity Number: HT942526KCRPIDA

Pre-Application Due: September 14, 2026

Application Due: September 28, 2026

This program announcement must be read in conjunction with the General Application Instructions, version [CD26_01](#).

Content

	Before You Begin	3
①	Basic Information Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	4
②	Eligibility Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	5
③	Program Description Describes the <u>program mission</u> and <u>intent of the Idea Development Award</u> ; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	6
④	Application Contents Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	12
⑤	Submission Requirements Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	20
⑥	Application Review Information Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	23
⑦	Federal Award Notices Outlines what a successful applicant can expect <u>if recommended for funding</u>	27
⑧	Post-Award Requirements References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	28
⑨	Other Information Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	30
	Appendix 1 Includes a checklist for all full application components to facilitate application submission	32
	Appendix 2 Acronym List	33
	Appendix 3 Change Log	35

Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

*Questions regarding
funding opportunity submission
requirements,
as well as technical assistance
related to pre-application or
intramural application submission.*

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

*Questions regarding
Grants.gov registration
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the *General Application Instructions (GAI)*.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#) | [Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.

Distinctive Features:

- **Partnering Principal Investigator Option:** Supports meaningful and productive partnerships between two investigators, termed the Initiating Principal Investigator (PI) and Partnering PI, collaborating on a single application. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI's application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly \$7.8M to fund approximately 8 Idea Development Award applications with total cost caps of \$900,000 for the IDA or \$1.2M for the IDA – Partnering PI Option. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), September 14, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 28, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, October 5, 2026
- **Peer Review:** December 2026
- **Programmatic Review:** March 2027

Announcement Type: Modified

Funding Opportunity Number: HT942526KCRPIDA

Assistance Listing Number: 12.420

Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of War \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

2.1.2. Principal Investigator

Investigators at or above the level of Assistant Professor (or equivalent) may be named by the organization as the Principal Investigator (PI), Initiating PI and/or Partnering PI.

An investigator may be named as a PI on only one FY26 Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) application.

Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Kidney Cancer Research Program (KCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the KCRP in 2017 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the KCRP from FY17 through FY24 totaled \$285 million (M). The FY26 appropriation is \$15M.

The KCRP's vision is to conquer kidney cancer through collaboration and discovery. The mission of the FY26 KCRP is to promote rigorous, innovative, high-impact research in kidney cancer for the benefit of Service Members, their Families, Veterans and the American Public. Within this context, the KCRP supports research and clinical care that addresses the following KCRP overarching strategic goals:

- Advance understanding of the biology of kidney cancer.
 - Encourage innovative ideas with high impact.
- Develop novel therapeutic strategies for the treatment of kidney cancer.
 - Identify new targets.
 - Develop pharmacological, immunological, genetic, microbiome or other interventions.
 - Optimize prognostic or predictive markers to assist with therapeutic decision-making.
 - Repurpose existing and currently approved interventions.
- Improve patient care for kidney cancer.
 - Integrate bench research with bedside care and promote translational research.
 - Invest in early-career kidney cancer physicians – next generation.
 - Facilitate multi-site collaborative clinical research development and clinical trials.
 - Identify strategies to improve outcomes in populations with unequal burden of kidney cancer.
- Increase research resources and collaborations in the area of kidney cancer.
 - Invest in innovative research conducted by the next generation of kidney cancer physicians and scientists.
 - Facilitate multi-site collaborative clinical research development and clinical trials.
 - Encourage experts inside and outside the field of kidney cancer to apply knowledge for advancements.
 - Foster collaborations that cross translational, disciplinary and institutional boundaries.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

3.1. Award History

The KCRP Idea Development Award mechanism was first offered in FY17. Since then, 610 Idea Development Award applications were received, and 124 were recommended for funding.

3.2. Intent of the Idea Development Award

The FY26 KCRP IDA mechanism intends to promote development of high-impact ideas that will advance the KCRP vision to conquer kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.

3.2.1. Focus Areas for the IDA

To meet the intent of the funding opportunity, applications must address at least one of the FY26 KCRP focus areas, as presented below.

- Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors, and the prevention of kidney cancer.
- Identify and develop new strategies for screening, early-stage detection, and accurate diagnosis and prognosis prediction of kidney cancers, including biomarkers and imaging and treatment of early-stage cancers.
- Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
- Develop novel, less toxic therapeutic strategies for all types of kidney cancer.
- Identify and implement strategies to improve the quality of life and survivorship for kidney cancer patients.
- Identify and implement strategies to enhance outcomes in high-risk kidney cancer patients, including those with limited access to health care, exposure to environmental factors and genetic/biological factors.
- Increase capacity and multi-disciplinary research through support and development of the next generation of kidney cancer researchers to improve patient care.

3.2.2. Kidney Cancer Type Selection for the IDA

Applications must address at least one of the kidney cancer disease types, as presented below.

- Clear cell renal tumors
 - Clear cell renal cell carcinoma (RCC)
 - Multilocular cystic renal neoplasm of low malignant potential
- Papillary renal tumors
 - Renal papillary adenoma
 - Papillary RCC
- Collecting duct carcinoma

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Oncocytic and chromophobe renal tumors
 - Oncocytoma
 - Chromophobe RCC
 - Other oncocytic tumors
- Renal cell carcinoma, unclassified
- Other renal tumors
 - Mucinous tubular and spindle cell carcinoma
 - Clear cell papillary renal cell carcinoma
 - Tubulocystic renal cell carcinoma
 - Acquired cystic disease associated renal carcinoma
 - Eosinophilic solid and cystic renal cell carcinoma
- Molecularly defined renal carcinomas
 - Succinate dehydrogenase deficient RCC
 - Fumarate hydratase deficient RCC
 - MiT family translocation RCC
 - TFE3 rearranged
 - TFEB altered
 - Elongin C (TCEB1) mutated
 - Anaplastic lymphoma kinase rearranged RCC
 - SMARCB1 deficient renal medullary carcinoma
- Wilms tumor (nephroblastoma)
- Renal sarcoma
- Von Hippel-Lindau associated with kidney cancer
- Kidney cancer type - not classified/not applicable

3.2.3. Key Elements for the IDA

- **Partnering PI Option:** The IDA includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to [Section 5.3, Submission Instructions](#).

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Research Approach:** The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of kidney cancer. Experimental strategies may be novel or may be based on strong rationale derived from previously published data and/or presented preliminary data. The feasibility of the research design and methods should be well-defined, and a clear plan articulated as to how the proposed goals of the project can be achieved. Additionally, the application should identify resources and access to those resources, supported by relevant documentation. The application should identify potential problems and pitfalls and address alternative approaches. If applicable, the application should include a statistical analysis plan for the proposed research, as well as a power analysis to support the design and sample size.
- **Preliminary Data:** Preliminary data to support the feasibility of the research hypotheses and approaches are required; however, these data do not need to be derived exclusively from the kidney cancer research field. Preliminary data may include published or unpublished results from the laboratory of the PI, Initiating PI or Partnering PI, or collaborators named on the application, as well as data from published literature relevant to kidney cancer.
- **Impact:** Proposed research projects should address a central critical issue or question in kidney cancer research or clinical care. High-impact research will, if successful, significantly advance current methods and concepts in at least one of the [FY26 KCRP Focus Areas](#).
- **Personnel:** Personnel are considered a crucial element of the FY26 KCRP IDA. The application should demonstrate the investigators' experience in kidney cancer through the PI's background, the qualifications of the research team and/or established collaborations. The application should document collaborations.

3.2.4. Other Important Considerations for the IDA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

[Clinical trials](#) are not allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#), [CONSORT](#), [SPIRIT](#) and [ARRIVE 2.0](#) guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

The following encouragement is broadly applicable across many CDMRP programs, including the KCRP. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced stage and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the [recommendations](#) and submit

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 KCRP priorities.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Single PI Option:

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **\$900,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Partnering PI Option:

The combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed **\$1.2M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

A separate award will be made to each PI's organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator (for the Partnering PI Option, one investigator from each partnering application) to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the KCRP Idea Development Award.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.



Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.



4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Include the focus area(s) under which the application will be submitted.

4.3. Full Application Components

Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an abbreviated full application package.

4.3.1. Full Application Components for the PI or Initiating PI

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (*Grants.gov submissions only*):



IMPORTANT: When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.

- **Attachment 1: Project Narrative (12-page limit): Upload as “ProjectNarrative.pdf”.**



Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and reasoning behind the proposed research. Describe previous experience most pertinent to the application. Preliminary data are required but need not originate from kidney cancer research. State the [FY26 KCRP Focus Area\(s\)](#) to be addressed.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
- **Specific Aims:** Concisely explain the project's specific aims. If this research project is part of a larger study, present only the tasks that this award would fund.
- **Research Strategy and Feasibility:**
 - Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail to allow for scientific evaluation and an assessment of overall project feasibility.
 - Address potential problem areas, and present alternative methods and approaches.
 - Clearly describe the statistical plan, the rationale for the statistical methodology, and an appropriate power analysis; include the statistical expertise available to support the analysis, if applicable.
 - Consult appropriate [guidelines](#) to ensure that relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
 - If human subjects or human anatomical samples will be used, include a plan for the recruitment of subjects or the acquisition of samples, and document the experience of the PI and/or collaborators in recruiting human subjects for similar projects. ***This award may not be used to conduct clinical trials.***
 - For all applications proposing [clinical research](#), describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study (including a description of the composition of the proposed study population in terms of sex, racial and ethnic group) and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of the application's Supporting Documentation ([Attachment 2](#)).
 - Describe how the clinical relevance of the anticipated findings will be determined, and whether the results will be validated in the appropriate patient cohorts, if applicable.
- **Personnel:** Explain the degree to which the proposed research demonstrates a critical understanding and in-depth knowledge of kidney cancer.
- **Partnering PI (for Partnering PI Option only):** Describe the specific contributions of the Partnering PI on the research project, and how the contribution of the partner will support the PI and the proposed project. These contributions should enhance the project's impact in the kidney cancer field.

Note: Impact should be addressed in [Attachment 6](#) and not in the Project Narrative ([Attachment 1](#)).

If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

other agreements required to access and publish data. Refer to the GAI, [Appendix 4](#), for additional considerations.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.**



There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support (one-page limit per letter is recommended): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet [eligibility criteria](#). If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Sex as a Biological Variable Strategy (two-page limit is recommended): Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance

Section Shortcuts


Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Inclusion Enrollment Report (*only required if clinical research and/or a clinical trial is proposed*): Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "[Public Health Service \(PHS\) Inclusion Enrollment Report](#)", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from IRB review) are exempt from this requirement.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".** 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the ideas and scientific rationale behind the proposed research project.


Focus Areas: State the [FY26 KCRP Focus Area\(s\)](#) to be addressed.

Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached.

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls.


Impact: Describe how the proposed research will yield critical discoveries, new avenues of investigation, or major advancements to prevent or cure kidney cancer.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".** 

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Summarize the objectives and rationale for the proposed research.
 - State the [FY26 KCRP Focus Area\(s\)](#) to be addressed.
 - What population will the research help, and how will it help them?
 - What are the potential clinical applications, benefits and risks of the anticipated outcomes? If the research is too basic for clinical applicability, describe the interim outcomes expected and their applicability to the field. What is the projected time it may take to achieve a clinically relevant outcome?
 - What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
 - Describe the impact that the proposed research project results might have on the field of kidney cancer research and/or patient care in the short term and/or long term for to Service Members, Veterans and/or their Families.
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.**  Refer to eBRAP for the [Suggested SOW Format](#).

Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.

For guidance on preparing the SOW, refer to either the [Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work](#) or [Example: Assembling a Generic Statement of Work](#), whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”.** This section should be written in a manner readily understood by readers without a background in science or medicine. Overly technical jargon should be avoided and technical terms, if any, should be defined.
- Describe how the proposed research is relevant to at least one of the [FY26 KCRP Focus Areas](#) in a way that is consistent with the program’s goals.
 - Describe the short-term impact: Detail the anticipated outcome(s)/product(s) (intellectual and/or tangible) that directly result from the proposed research to drive the kidney cancer field forward and support new avenues for research or clinical care.
 - Describe the long-term impact: Explain the potential long-term impact of this study on the field of kidney cancer research and/or patient care.
 - Describe how the proposed research will, whether in the short or long term, lead to an original and important contribution toward advancing basic, translational, or clinical kidney cancer research, or to improvements in the quality of life of individuals with kidney cancer.
 - If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information



- **Attachment 7: Animal Research Plan (three-page limit): Upload as “AnimalResPlan.pdf”. (*Attachment 7 is only applicable and required for applications proposing animal studies.*)**

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the [ARRIVE guidelines 2.0](#) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
 - Summarize the procedures to be conducted. Describe how the study will be controlled.
 - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
 - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
 - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis and identification of the primary endpoint(s).
- **Attachment 8: Partnership Statement (one-page limit): Upload as “Partnership.pdf”. (*Attachment 8 is only applicable and required for applications to the Partnering PI Option.*)** Describe the partnership and combined expertise and different strengths of the Initiating and Partnering PI that are critical for the research strategy and completion of the SOW. Describe how the combined effort will be synergistic and produce an outcome greater than what could be achieved by independent efforts. Outline the contribution and time commitment of the partner and how they will have equal intellectual input on the design, conduct and analysis of the project. Describe how the PI will manage the collaboration and workflow to optimize research efforts.
- **Attachment 9: Post-Award Progression Plan (two-page limit): Upload as “Progression.pdf”.** The KCRP requires applicants to provide a feasible implementation plan for the research proposed and how the research will ultimately lead to clinical application for intended populations. Applicants should identify the next logical and feasible steps following the period of performance. Assuming the project is successful in all its aims:
 - Outline the next immediate and subsequent logical steps to be taken following the period of performance to progress the research to clinical applicability. Describe the timeline needed with defined milestones. If further research is required, describe why this additional study is needed and how those outcomes would contribute to progressing the research toward clinical utility. Include steps necessary for regulatory interactions, if applicable.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Describe how any bidirectional feedback and dissemination from the kidney cancer community will be integrated into the progression of this research.
- Describe collaborations and other resources (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees, training providers/resources) that are in place or will be established to reach the milestones described above.
- As appropriate, discuss ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award.
- **Attachment 10: Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP. 
- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form (*if applicable*): Upload as “IGBudget.pdf”.** If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP. 

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s), or vice versa, even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed budget information.

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) (*if applicable, Grants.gov submissions only*)

4.3.2. Full Application Components for the Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See [Appendix 1](#) for a checklist of the full application components required for the Partnering PI.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

(a) SF424 [Research & Related](#) Application for Federal Assistance Form (*Grants.gov Submissions Only*):

(b) Attachments:

- [Attachment 5: Statement of Work \(three-page limit\): Upload as “SOW.pdf”](#). Each PI must submit an identical copy of a jointly created SOW.
- [Attachment 10: Representations \(Grants.gov submissions only\): Upload as “RequiredReps.pdf”](#).
- [Attachment 11: Suggested Intragovernmental/Intramural Budget Form: Upload as “IGBudget.pdf”](#).

(c) [Additional Application Materials](#):

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI(s) should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed budget information.

iii. Project/Performance Site Location(s) Form

iv. Research & Related Subaward Budget Attachment(s) Form (*if applicable, Grants.gov submissions only*)

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526KCRPIDA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or Initiating PI through [eBRAP](#), including the submission of contact information for the Partnering PI if selecting the Partnering PI Option. i

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.

Partnering PI Option: After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PI must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Partnering PI must register in eBRAP.


Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI. Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:


Application Includes:	Select Mechanism Option:
Single PI	Idea Development Award
Initiating PI and Partnering PI	Idea Development Award – Partnering PI Option

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

eBRAP Submissions: Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends. 

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

Section Shortcuts


Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal. 

Members of the FY26 KCRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). **A list of the [FY26 KCRP Programmatic Panel members](#) can be found on the CDMRP website.**

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**
 - To what degree the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature, preliminary data and/or logical reasoning.
 - To what degree the proposed research demonstrates a critical understanding and in-depth analysis of kidney cancer.
 - How well the hypotheses or objectives, specific aims, experimental design, methods and analyses are developed and integrated into the project.
 - To what degree the research design and methods can successfully achieve the goals of the proposed project.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- To what extent the application identifies potential problems and addresses alternative approaches.
 - Whether the application includes an appropriate statistical plan with power analysis, if applicable. How well the described statistical plan will evaluate the results, and whether it is appropriate for the sample size according to the power analysis.
 - Whether the application demonstrates the availability of resources such as tissue, data or human subjects, if applicable.
 - How well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
 - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.
 - How well the animal study (or studies) is designed to achieve the objectives, including the choice of model and endpoints/outcome measures to be used, if applicable.
 - How well the study (or studies) is designed to achieve reproducible and rigorous results, including controls, sample size estimation, blinding, randomization and data handling.
- **Impact**
 - Whether the application addresses at least one of the [FY26 KCRP Focus Areas](#).
 - To what extent the proposed research will, whether in the short or long term, lead to an original and important contribution toward advancing basic, translational, or clinical kidney cancer research, or to improvements in the quality of life of individuals with kidney cancer.
 - To what degree the anticipated short-term outcome(s)/product(s) (intellectual and/or tangible) will drive the kidney cancer field forward and support new avenues for research or clinical care.
 - How well the anticipated long-term gains from this research will yield relevant results for kidney cancer research or patient care.
 - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
 - **Personnel**
 - How appropriate the expertise and levels of effort are for successful conduct of the proposed work.
 - **Partnering PI Option:** How the partners' combined expertise will better address the research question than independent research efforts.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
 - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- **Budget**
 - Whether the budget is appropriate for the proposed research.
- **Environment**
 - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
 - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
 - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 KCRP, as evidenced by the following:
 - Adherence to the intent of the funding opportunity
 - Programmatic relevance to the [FY26 KCRP Focus Areas](#)
 - Program portfolio balance and composition
 - Relative impact

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. **CDMRP will NOT provide an invitation to submit a full application after pre-application submission.** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. **The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the KCRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

8. Post-Award Requirements


8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Terms and Conditions](#) for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB or Ethics Committee (EC) review. 

8.2. Reporting

Annual technical progress reports, as well as a final technical progress report, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

PHS Inclusion Enrollment Reporting (***required for research proposing clinical research***): Enrollment reporting on the basis of sex, race and/or ethnicity will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

Award Expiration Transition Plan: [An Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

8.3. Additional Requirements

An organizational transfer of an award supporting the Initiating PI or Partnering PI is discouraged and will be evaluated on a case-by-case basis.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- The Pre-application was not submitted.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 KCRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization):
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- More than one application is received naming the same PI, Initiating PI and/or Partnering PI. Only the first application received will be accepted; additional applications will be administratively withdrawn.
- The PI does not meet the [eligibility criteria](#).
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.
- The application does not address at least one of the [FY26 KCRP Focus Areas](#).
- The application does not include preliminary data.
- A clinical trial is proposed.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
SF424 Research & Related Application for Federal Assistance <i>(Grants.gov submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
Summary (Tab 1) and Application Contacts (Tab 2) <i>(eBRAP submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
Attachments		
Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
Supporting Documentation – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
Technical Abstract – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
Lay Abstract – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
Statement of Work – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Impact Statement – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>	
Animal Research Plan <i>(if applicable)</i> – Attachment 7, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>	
Partnership Statement <i>(if applicable)</i> – Attachment 8, upload as “Partnership.pdf”	<input type="checkbox"/>	
Post-Award Progression Plan <i>(if applicable)</i> – Attachment 9, upload as “Progression.pdf”	<input type="checkbox"/>	
Representations <i>(Grants.gov submissions only)</i> – Attachment 10, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Suggested Intragovernmental/Intramural Budget Form <i>(if applicable)</i> – Attachment 11, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Budget	<input type="checkbox"/>	<input type="checkbox"/>
Project/Performance Site Location(s)	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Subaward Budget Attachment(s) <i>(if applicable)</i>	<input type="checkbox"/>	<input type="checkbox"/>

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IDA	Idea Development Award
IRB	Institutional Review Board
KCRP	Kidney Cancer Research Program
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RCC	Renal Cell Carcinoma
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Appendix 3. Change Log

June 23, 2026

- Page 1: Updated pre-application and application submission deadlines
- Section 1, page 4: Updated pre-application and application submission deadlines and the end of application verification period